These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33377659)

  • 1. CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-κB oncogenic signaling.
    Hu B; Xu Y; Li YC; Huang JF; Cheng JW; Guo W; Yin Y; Gao Y; Wang PX; Wu SY; Zhou J; Fan J; Yang XR
    Clin Transl Med; 2020 Dec; 10(8):e233. PubMed ID: 33377659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
    Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
    EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.
    Cao C; Vasilatos SN; Bhargava R; Fine JL; Oesterreich S; Davidson NE; Huang Y
    Oncogene; 2017 Jan; 36(1):133-145. PubMed ID: 27212032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-8 induces sorafenib resistance via binding with c-Rel to mediate NF-κB signaling in hepatocellular carcinoma.
    Liu HF; Xie YK; Zhong BY; Zhang JH; Song CX; Liu YW; Yang Y; Xie BH
    Cell Biol Int; 2022 Feb; 46(2):213-221. PubMed ID: 34719075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway.
    Zhou C; Liu C; Liu W; Chen W; Yin Y; Li CW; Hsu JL; Sun J; Zhou Q; Li H; Hu B; Fu P; Atyah M; Ma Q; Xu Y; Dong Q; Hung MC; Ren N
    Theranostics; 2020; 10(10):4627-4643. PubMed ID: 32292519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
    Wu J; Chai H; Li F; Ren Q; Gu Y
    Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma.
    Yu J; Wang N; Gong Z; Liu L; Yang S; Chen GG; Lai PBS
    Oncogene; 2021 Jan; 40(3):492-507. PubMed ID: 33184472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification of DDR2 mediates sorafenib resistance through NF-κB/c-Rel signaling in hepatocellular carcinoma.
    Liu QQ; Liu YW; Xie YK; Zhang JH; Song CX; Wang JZ; Xie BH
    Cell Biol Int; 2021 Sep; 45(9):1906-1916. PubMed ID: 33969575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
    Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
    Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
    Feng F; Jiang Q; Cao S; Cao Y; Li R; Shen L; Zhu H; Wang T; Sun L; Liang E; Sun H; Chai Y; Li X; Liu G; Yang R; Yang Z; Yang Y; Xin S; Li BA
    Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
    Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF-κB pathway.
    Yang Q; Xie B; Tang H; Meng W; Jia C; Zhang X; Zhang Y; Zhang J; Li H; Fu B
    J Exp Clin Cancer Res; 2019 Jun; 38(1):263. PubMed ID: 31208444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
    Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
    Yamashita M; Wada H; Eguchi H; Ogawa H; Yamada D; Noda T; Asaoka T; Kawamoto K; Gotoh K; Umeshita K; Doki Y; Mori M
    Int J Oncol; 2016 Jul; 49(1):89-98. PubMed ID: 27121124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
    Deng L; Sun J; Chen X; Liu L; Wu D
    J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.